ONCOLOGIX TECH (OCLG) Stock News

OCLG OTC

05/02/2022 02:45 PM

News

DNAGO and Oncologix Tech, Inc. Announce Agreement for Business Combination to Create Publicly Listed Company Focused on Providing clinical genetic testing on all 20,000+ genes encompassing 7,000+ rare genetic diseases at affordable price

Rhea-AI Summary

On May 2, 2022, Oncologix Tech, Inc. (OTC: OCLG) announced a definitive business combination agreement with DNAGO.Ai, a company specializing in clinical genetic testing. Post-combination, OCLG will be renamed DNAGO and continue operations focused on genetic testing for over 7,000 rare diseases. The transaction is expected to finalize in Q2 2022, pending shareholder approval. CEO Frank I Igwealor resigned, with Madeline Choi appointed as the new CEO. The firm emphasizes its mission to make affordable genetic testing accessible through advanced AI technology.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-18.18%

FAQ

What is the current stock price of ONCOLOGIX TECH (OCLG)?

The current stock price of ONCOLOGIX TECH (OCLG) is $0.0001 as of September 28, 2026.

What is the market cap of ONCOLOGIX TECH (OCLG)?

The market cap of ONCOLOGIX TECH (OCLG) is approximately 166.2K.